Pharma and wellness are converging on longevity
The latest: GLP-1 profits are fueling healthcare’s next frontier as companies expand into prevention, age-related disease, and emerging therapeutics.
Hims. The telehealth company named Dr. Anant Vinjamoori as chief medical officer. A longevity expert, Vinjamoori said GLP-1s are “just the beginning,” pointing to a wave of new therapies spanning peptides, metabolic health, and regenerative medicine — where delivery, not discovery, is the “defining challenge.”
Novo Nordisk. Beyond obesity, CEO Mike Doustdar told Bloomberg GLP-1s could pull the company into longevity, aesthetics, and age-related conditions: “We have to be obsessed with what our patients want.” In his view, weight loss may be “an appendix of a different purpose.”
Eli Lilly. Armed with billions from Mounjaro and Zepbound, Lilly is accelerating acquisitions and AI drug discovery. Executives described the current moment as a “generational opportunity” to redeploy GLP-1 profits into new therapeutic categories.
Takeaway: More than blockbuster weight-loss drugs, GLP-1s may prove to be the catalyst that bankrolls the next era of medicine.
